WeVote
Log In

Bill

Bill

S 694

PLASMA Act

119th Congress Introduced by Ted Budd and 3 co-sponsors

PLASMA Act aims to preserve life-saving access to specialty medicines in America, affecting patients, providers, and insurers; currently before the Senate Finance Committee.

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 694

Summary: S. 694 – PLASMA Act (Preserving Life-saving Access to Specialty Medicines in America Act)

Overview

S. 694, introduced in the U.S. Senate on February 24, 2025, is titled the PLASMA Act. The bill is introduced and referred to the Committee on Finance. The official short title indicates the purpose is to preserve life-saving access to specialty medicines in America. A House companion bill exists (HR 1476).

Purpose and Intent

  • Full text not provided in the summary. Based on the title and citation, the Act aims to preserve or protect access to life-saving, specialty medicines in the United States.
  • The acronym PLASMA stands for the Preserving Life-saving Access to Specialty Medicines in America Act.

Legislative Details

  • Introduction and Status
    • Introduced: February 24, 2025
    • Status: Read twice and referred to the Committee on Finance (Senate)
  • Committee Action
    • Referred to the Senate Committee on Finance (no further action detailed in the provided information)
  • Sponsors
    • Primary sponsor: Sen. Thom Tillis
    • Cosponsors: Sen. Mark Kelly, Sen. Ted Budd, Sen. Alex Padilla
    • This set of sponsors indicates bipartisan involvement (two Republicans and two Democrats).
  • Related Legislation
    • Companion bill: HR 1476 (House of Representatives)

Who or What Would Be Affected

  • The bill’s stated aim suggests impact on access to specialty medicines, which could involve patients, healthcare providers, insurers, and potentially federal health programs (e.g., Medicare/Medicaid). Specific provisions, eligibility criteria, coverage requirements, pricing or reimbursement mechanisms, and implementation details are not included in the available summary.

Procedural and Timeline Aspects

  • The bill has been introduced and referred to the Senate Committee on Finance, indicating it will proceed through committee consideration before any floor action.
  • The existence of a House companion (HR 1476) suggests potential parallel activity in the House of Representatives.

Key Considerations and Next Steps

  • To understand the full impact, the text of S. 694 is needed to identify:
    • The exact policy mechanisms (coverage requirements, pricing, reimbursement, incentives, regulatory changes)
    • Fiscal implications and budgetary provisions
    • Implementation timelines and enforcement
    • Any transitional provisions for existing patients or programs
  • Readers should compare the Senate bill with its House companion to see how the proposals align and what differences may emerge during legislative consideration.

If you’d like, I can track updates on committee hearings, amendments, or floor actions as they become available.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.